Your browser is no longer supported. Please, upgrade your browser.
Cogent Biosciences, Inc.
Index- P/E- EPS (ttm)-12.88 Insider Own0.10% Shs Outstand37.19M Perf Week-3.46%
Market Cap322.88M Forward P/E- EPS next Y-1.74 Insider Trans0.00% Shs Float30.79M Perf Month2.25%
Income-179.20M PEG- EPS next Q-0.41 Inst Own91.50% Short Float8.42% Perf Quarter-27.46%
Sales7.90M P/S40.87 EPS this Y-287.10% Inst Trans214.03% Short Ratio6.12 Perf Half Y-14.62%
Book/sh6.47 P/B1.34 EPS next Y11.20% ROA-155.60% Target Price- Perf Year518.20%
Cash/sh- P/C- EPS next 5Y- ROE-489.10% 52W Range1.36 - 14.88 Perf YTD-23.06%
Dividend- P/FCF- EPS past 5Y- ROI-66.40% 52W High-42.00% Beta-
Dividend %- Quick Ratio18.70 Sales past 5Y21.40% Gross Margin- 52W Low534.56% ATR0.56
Employees15 Current Ratio18.70 Sales Q/Q-100.00% Oper. Margin- RSI (14)49.57 Volatility5.28% 7.20%
OptionableNo Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume1.45 Prev Close8.64
ShortableYes LT Debt/Eq0.00 EarningsMar 16 BMO Payout- Avg Volume423.68K Price8.63
Recom1.30 SMA20-0.23% SMA50-1.99% SMA200-14.77% Volume514,159 Change-0.12%
Dec-23-20Initiated Piper Sandler Overweight $22
Oct-14-20Initiated Ladenburg Thalmann Buy $4
Apr-06-21 07:00AM  
Mar-17-21 02:27AM  
Mar-16-21 07:00AM  
Feb-22-21 07:00AM  
Feb-18-21 07:00AM  
Feb-11-21 07:00AM  
Dec-04-20 05:16PM  
Dec-01-20 11:08PM  
Nov-30-20 04:01PM  
Nov-20-20 07:00AM  
Nov-18-20 09:00AM  
Nov-12-20 04:30PM  
Nov-09-20 07:00AM  
Nov-05-20 07:00AM  
Oct-26-20 07:00AM  
Apr-01-20 01:42AM  
Nov-13-19 06:22PM  
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies to treat genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. Cogent Biosciences, Inc. has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of CGT9486 and CGT0206 inhibitors. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.